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ENGINEERED TISSUES DERIVED FROM INDUCED-PLURIPOTENT STEM CELLS (IPSCs) FOR DISEASE
MODELING, DRUG DISCOVERY, AND REPLACEMENT THERAPIES*
A Synthetic Gene Circuit for Self-Regulating Delivery
of Biologic Drugs in Engineered Tissues
Lara Pferdehirt, MS,1–4,** Alison K. Ross, MS,1–4,** Jonathan M. Brunger, PhD,5 and Farshid Guilak, PhD1–4
Transient, resolving inflammation plays a critical role in tissue repair and regeneration. In the context of joint
disease, however, chronic inflammation following injury or with osteoarthritis can lead to irreversible articular
cartilage degradation and joint pain. Developing tissue engineering strategies for the regeneration of articular
cartilage remains challenging due to the harsh inflammatory environment of an injured or arthritic joint, which
can promote degradation of engineered tissues as well as native articular cartilage. Here, we developed an
artificial gene circuit for controlled, cell-based delivery of biologic drugs, based on a nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB)-responsive synthetic promoter. Using lentivirus-based gene
therapy, we engineered murine induced pluripotent stem cells (iPSCs) capable of attenuating inflammation
through controlled release of an anti-inflammatory drug, interleukin-1 receptor antagonist (IL-1Ra), subse-
quently inhibiting gene circuit activation in a self-regulating manner. Murine iPSCs were transduced with the
synthetic gene circuit either in monolayer or through biomaterial-mediated transduction. Cells were maintained
in monolayer or differentiated into cartilage constructs and stimulated with different doses of interleukin 1 alpha
(IL-1a) to determine the ability of this synthetic NF-kB responsive system to inhibit inflammation and protect
tissue-engineered constructs. In response to IL-1a, cells produced high levels of IL-1Ra, which inhibited
inflammatory signaling and protected tissue-engineered cartilage from proteoglycan degradation. Our results
show that the combination of gene therapy and tissue engineering can be used to successfully create iPSCs
capable of producing biologic drugs in a controlled manner. This self-regulating system provides a tool for cell-
based drug delivery as the basis for a novel therapeutic approach for a variety of diseases.
Keywords: synthetic biology, gene therapy, arthritis, regenerative medicine, stem cells
Impact Statement
We engineered a synthetic transcription system based on nuclear factor kappa-light-chain-enhancer of activated B cells
signaling that can attenuate the effects of the inflammatory cytokine interleukin (IL)-1a in a self-regulating manner. This
system responds in a time- and dose-dependent manner to rapidly produce therapeutic levels of IL-1 receptor antagonist (IL-
1Ra). The use of lentiviral gene therapy allows this system to be utilized through different transduction methods and in
different cell types for a variety of applications. Broadly, this approach may be applicable in developing autoregulated
biologic systems for tissue engineering and drug delivery in a range of disease applications.
Introduction
Osteoarthritis (OA) is a debilitating joint disease thatcauses severe pain and loss of joint function, affecting
over 32 million adults in the United States alone.1 OA is
characterized by the degeneration of articular cartilage, the
hyaline cartilage that covers the articulating surfaces of
bones in diarthrodial joints. Because articular cartilage is
avascular, aneural, and alymphatic, it lacks an intrinsic
ability to repair.2 While there are many risk factors for
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OA—including injury, aging, metabolic disorders, obesity,
and genetics—a common pathway for the pathogenesis and
progression of joint degeneration and pain involves the
proinflammatory activity of several cytokines, particularly
the interleukin-1 (IL-1) family of cytokines, including IL-1a
and IL-1b, and tumor necrosis factor-a (TNF-a).3 These
cytokines primarily signal via the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB) to induce ex-
tracellular matrix (ECM) degradation through the inhibition
of anabolic activities and enhanced production of degradative
enzymes and catabolic cytokines, particularly in articular
chondrocytes.4,5 Furthermore, inflammation can significantly
inhibit repair of cartilage and other joint tissues, as several
studies have shown high sensitivity of stem cells and en-
gineered cartilage to cytokines such as IL-1 and TNF.6–9
IL-1 receptor antagonist (IL-1Ra, anakinra), a competitive
antagonist of IL-1, has been shown to alleviate symptoms
of rheumatoid arthritis (RA) and post-traumatic OA.10–12
Furthermore, several gene therapy approaches to deliver IL-
1Ra to the joints of patients with RA and OA are in progress
or pending.5,13,14 However, despite the potential for success
of anti-cytokine drugs and gene therapy approaches, there
are currently no effective disease-modifying treatments to
address both the symptoms and structural change of OA.14–16
Additionally, the inability of these approaches to accom-
plish a sustained delivery of biologic drugs in a dynamically
and spatially controlled manner is an important limitation.
Anti-cytokine therapies are often delivered at high doses,
which may have significant off-target effects, including an
increased susceptibility to infection and certain autoim-
mune diseases,17 as well as limited tissue regeneration and
repair.18–20 Therefore, the long-term success of stem cell–
based therapies for cartilage repair or OA may require
engagement of intrinsic cellular abilities to regulate the in-
flammatory environment of the joint.
To address these limitations, tissue engineering and gene
therapy approaches can be combined to create a cartilaginous
tissue that is capable of replacing damaged tissue while de-
livering therapeutic drugs to diseased joints.21 Additionally,
by using both gene delivery and synthetic biology, cells can
be transduced ex vivo with expression vectors designed
to produce a desired gene through specific inputs.22,23 Fur-
thermore, the implantation of tissue-engineered constructs
allows for localized delivery of biologic drugs to specific
sites in the body.
The overall goal of this study was to create self-regulating
(i.e., feedback-controlled) stem cells capable of attenuating
inflammation in a prescribed manner for a controlled release
of anti-inflammatory molecules. We engineered a synthetic
transcriptional regulator system capable of producing a
therapeutic drug, and packaged it into a lentiviral vector to
allow for transduction into various cell types and through
different transduction strategies. Specifically, we developed
an NF-kB-inducible synthetic promoter that controls the
release of a biologic drug, IL-1Ra, to maintain tissue ho-
meostasis in response to the activation of NF-kB in a long-
term and sustained manner (Fig. 1). We utilized this lenti-
viral vector to create murine induced pluripotent stem cells
(iPSCs) capable of sensing and responding to inflammation.
Additionally, we show the proof-of-concept for site-specific,
scaffold-mediated delivery24,25 of this lentivirus to iPSCs.
The transduced iPSCs were chondrogenically differentiated
into articular cartilage tissue to determine the efficacy of this
vector in protecting engineered tissue against cytokine-
induced degradation. We hypothesized that this NF-kB-
inducible biologic drug delivery system will allow for
controlled, self-regulating production of anti-inflammatory
molecules in direct response to dynamic changes in in-
flammatory stimuli. This type of cell-based approach could
provide an effective method to treat OA and chronic in-
flammatory diseases while overcoming limitations of cur-
rent drug delivery techniques.
Materials and Methods
Overall strategy
The overall strategy for this work was to create a syn-
thetic transcription system that is activated by inflammatory
cytokines and, when incorporated into a lentiviral vector,
can be readily delivered to different types of cells for ap-
plications in cell therapy or tissue engineering. Cells trans-
duced by the lentiviral vectors were programmed to express
anti-inflammatory biologic drugs downstream of the syn-
thetic promoter, providing a negative feedback system that
blocks the action of an inflammatory cytokine (Fig. 1). Here,
we specifically tested the ability of our synthetic transcrip-
tion system to protect engineered cartilage from its intrinsic
response to inflammatory cytokines through three different
methods: in monolayer, in tissue-engineered cartilage, and
with biomaterial-mediated delivery of vectors.
Vector design
A synthetic NF-kB-inducible promoter was designed to
incorporate multiple NF-kB response elements that drive a
target gene of interest.26 Briefly, a synthetic promoter was
developed containing five consensus sequences approxi-
mating the NF-kB canonical recognition motif based on
genes that are upregulated by inflammatory challenge:
InfB1, Il6, Mcp1, Adamts5, and Cxcl10.26,27 Murine Il1rn or
firefly luciferase from the pGL3 basic plasmid (Promega)
was cloned downstream of this synthetic promoter; a TATA
box derived from the minimal CMV promoter was cloned
between the synthetic promoter and downstream target
genes; and an NF-kB-negative regulatory element (NRE—
5¢-AATTCCTCTGA-3¢)28 was cloned upstream of the pro-
moter to reduce background signal (Fig. 1). This engineered
NRE-IL1Ra cassette results in transgene expression when
the promoter is activated in response to NF-kB-based in-
flammatory stimuli, resulting in a ‘‘self-regulating’’ system.
A constitutive control vector was also tested using murine
Il1rn cloned into the lentiviral transfer vector (No. 12250;
Addgene) downstream of the EF1a promoter sequence29
(EF1a-IL1Ra) using Gibson Assembly.30 A nuclear-targeted
green fluorescent protein (GFP)31 (No. 11680; Addgene) was
cloned into a constitutive, lentiviral vector32 (No. 11645;
Addgene) and was used as a transduction control (GFP).
Lentivirus production
HEK293T cells were co-transfected with an expression
transfer vector, second-generation packaging plasmid psPAX2
(No. 12260; Addgene), and an envelope plasmid pMD2.G (No.
12259; Addgene) by calcium phosphate precipitation to make
vesicular stomatitis virus glycoprotein pseudotyped lentivirus.33
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The expression transfer vectors include the NRE-IL1Ra, NRE-
Luc, EF1a-IL1Ra, and GFP plasmids. The lentivirus was stored
at -80C until further use. The functional titer of each virus
group was determined via quantitative real-time polymerase
chain reaction to determine the number of lentiviral DNA copies
integrated into the genome of transduced HeLa cells.33
Cell culture and differentiation
Murine iPSCs, generated from tail fibroblasts from adult
C57BL/6 mice and validated for pluripotency as described
by Diekman et al.,34,35 were maintained on mitomycin C-
treated mouse embryonic fibroblasts (Millipore). To track
inflammatory activity in cells, an iPSC reporter cell line was
created via the CRISPR-Cas9 genome editing system to
incorporate firefly luciferase downstream of the Ccl2 locus
(Ccl2-Luc).26 In this cell line, proinflammatory signaling
activates Ccl2 promoter activity, resulting in the transcrip-
tion of luciferase.36
Unedited and Ccl2-Luc cells were then differentiated to-
ward a mesenchymal state using a high-density micromass
culture. Differentiation medium contained Dulbecco’s mod-
ified Eagle’s medium high glucose (DMEM-HG); 1% culture
medium supplement containing recombinant human insulin,
human transferrin, and sodium selenite (ITS+); minimum
essential medium (MEM) nonessential amino acids; 55mM 2-
mercaptoethanol; 24 ng/mL gentamicin; 50mg/mL l-ascorbic
acid; and 40mg/mL l-proline. On days 3–5, this medium was
supplemented with 100 nM dexamethasone and 50 ng/mL
bone morphogenetic protein 4 (BMP-4; R&D Systems).35
After 15 days of culture, the micromasses were dissociated
with pronase and collagenase type II and the predifferentiated
iPSCs (PDiPSCs) were plated on gelatin-coated dishes in
expansion medium containing DMEM-HG, 10% fetal bovine
serum, 1% ITS+, MEM nonessential amino acids, 55mM
2-mercaptoethanol, 1% penicillin/streptomycin, 50mg/mL
l-ascorbic acid, 40mg/mL l-proline, and 4 ng/mL of basic
fibroblast growth factor (bFGF; R&D Systems). These cells
were then expanded, transduced, and either used for mono-
layer experiments or in pellet cultures to produce engineered
cartilage to evaluate the ability of these cells to protect
against inflammation.
FIG. 1. Overview of synthetic promoter design and experimental approach. A synthetic promoter was designed with five
NF-kB recognition motifs upstream of Il1rn (gene for IL-1Ra) to create an NF-kB-inducible promoter. An NF-kB NRE was
inserted upstream of the promoter to reduce background signal. In a separate vector, the EF1a constitutive promoter was
used to drive a continuous expression of IL-1Ra. iPSCs were transduced with lentivirus delivering an EF1a constitutive
promoter that drives the expression of IL-1Ra, or an NF-kB-inducible promoter that drives the expression of IL-1Ra. In the
presence of IL-1a, the synthetic promoter is activated and produces IL-1Ra, preventing IL-1a from binding to the IL-1
receptor and inhibiting the activation of inflammatory cascades within the cell. IL-1a, interleukin 1 alpha; IL-1Ra,
interleukin-1 receptor antagonist; iPSCs, induced pluripotent stem cells; NF-kB, nuclear factor kappa-light-chain-enhancer
of activated B cells; NRE, negative regulatory element. Color images are available online.
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Lentiviral transduction and culture of PDiPSCs
For initial characterization, PDiPSCs were transduced with
the NRE-Luc virus. For all other monolayer experiments,
passage 4 PDiPSCs and Ccl2-Luc cells were transduced with
NRE-IL1Ra and EF1a-IL1Ra virus, and non-transduced
(NT) cells were used as control.
In pellet experiments, PDiPSCs were transduced at
passage 1 with NRE-IL1Ra, EF1a-IL1Ra, or GFP virus.
Passage 1 cells were trypsinized, and pellet cultures were
created by centrifuging 250k cells at 200 g for 5 min. The
pellets were cultured in chondrogenic media containing
DMEM-HG, 1% ITS+, MEM nonessential amino acids,
55 mM 2-mercaptoethanol, 1% penicillin-streptomycin,
50 mg/mL l-ascorbic acid, 40 mg/mL l-proline, 100 nM
dexamethasone, and 10 ng/mL transforming growth factor-
b3 (TGF-b3) for 21 days.35
For all monolayer and pellet studies, transduction media
consisted of expansion medium supplemented with 4 mg/mL
polybrene (Sigma-Aldrich) and the desired number of viral
particles to achieve a multiplicity of infection = 3. Trans-
duction media were exchanged with expansion medium
after 24 h of transduction.
Biomaterial-mediated delivery
Biomaterial-mediated lentiviral transduction was tested
using a model system based on poly(e-caprolactone) (PCL;
molecular weight 70,000–90,000; Sigma-Aldrich), a scaf-
fold material commonly used for cartilage tissue engineer-
ing.37,38 PCL was dissolved in glacial acetic acid at a 10%
wt/vol ratio. Tissue culture-treated plates were coated with
the dissolved PCL, and the acid was evaporated overnight.
The acid was quenched with 1 N NaOH, washed with
phosphate buffered saline (PBS), and sterilized with an
ethanol gradient. Plates were then incubated in 0.002%
poly-l-lysine (PLL) solution (Sigma-Aldrich). PLL was
aspirated, and two groups of lentivirus (NRE-IL1Ra and
EF1a-IL1Ra) or PBS for NT controls were added to the
plates and allowed to incubate for 4 h at 37C.24,37 After
virus immobilization, viral supernatant was aspirated, wells
were washed with PBS, and passage 4 PDiPSCs and Ccl2-
Luc control cells were plated in the wells. After an addi-
tional 3 days of culture, the ability of these cells to respond
to and attenuate inflammation was evaluated through a lu-
minescence activity assay, protein production, and gene
expression analysis.
Inflammatory challenge
To evaluate the response of the synthetic promoter to
inflammatory cytokines, unedited PDiPSCs transduced with
NRE-Luc were challenged with 1 ng/mL IL-1a or 20 ng/mL
TNF and evaluated at 72 h after challenge.
To determine the sensitivity and kinetics of the synthetic
promoter, all groups of Ccl2-Luc and unedited PDiPSCs
(NT, NRE-IL1Ra, and EF1a-IL1Ra) were evaluated at 0, 4,
12, 24, and 72 h post supplementation of media with 0.05,
0.1, 0.5, or 1 ng/mL IL-1a and removal of bFGF. Control
cells were cultured in the absence of IL-1a.
For characterizing the pellets’ response to inflammation,
after 21 days of chondrogenic culture, pellets were chal-
lenged with 0.5 or 1 ng/mL IL-1a and removal of TGF-b
and dexamethasone for 72 h. Control pellets were cultured
in the absence of IL-1a.
Inflammation activity assay
Luciferase activity from NRE-Luc transduced cells and
Ccl2-Luc cells in all monolayer experiments was measured
using the BrightGlo Luminescence kit (Promega) and a
Cytation5 plate reader (Biotek). Luciferase activity is re-
ported as a fold change of IL-1a-stimulated cells over
control cells cultured without IL-1a (n = 4–6).
Gene expression
Unedited PDiPSCs from monolayer studies and pellets
were harvested for quantitative, reverse transcription poly-
merase chain reaction (qRT-PCR) after inflammatory chal-
lenge (n = 4). Monolayer cells were rinsed in PBS, lysed in
Buffer RL (total RNA purification; Norgen Biotek), and
stored at -80C until RNA isolation. Pellets of engineered
cartilage tissue were rinsed in PBS and stored at -80C until
RNA isolation. Pellets were homogenized using a miniature
bead beater. RNA isolation was carried out following the
manufacturer’s protocol (Norgen Biotek). Reverse transcrip-
tion was performed using Superscript VILO complementary
DNA (cDNA) master mix (Invitrogen). qRT-PCR was per-
formed using Fast SyBR Green master mix (Applied Bio-
systems) following the manufacturer’s protocol. Primer pairs
(Supplementary Table S1) were synthesized by Integrated
DNA Technologies, Inc. Fold changes were calculated using
the DDCT method and are shown relative to the 0 h no cy-
tokine, NT control samples for monolayer experiments, or
GFP pellets without cytokines. For samples with no ampli-
fication, CT threshold was set to the cycle limit.
Enzyme-linked immunosorbent assays
Culture media were collected from all unedited PDiPSC
monolayer and pellet samples after inflammation challenge
and stored at -20C. IL-1Ra concentration was measured
with DuoSet enzyme-linked immunosorbent assay (ELISA)
specific to mouse IL-1Ra/IL-1F3 (n = 4; R&D Systems).
Each sample was measured in technical duplicates. Absor-
bance was measured at 450 and 540 nm.
Biochemical analysis of pellet cultures
After 72 h of inflammatory challenge, pellets were wa-
shed with PBS and stored at -20C until processing. Pellets
were digested overnight in 125 mg/mL papain at 65C for
biochemical analysis. DNA content was measured with
PicoGreen assay (Thermo Fisher), and total sulfated gly-
cosaminoglycan (sGAG) content was measured using a 1,9-
dimethylmethylene blue assay at 525 nm wavelength39
(n = 4).
Histological processing of pellet culture
After 72 h of cytokine challenge, pellets were washed
with PBS and fixed in 10% neutral buffered formalin for
24 h, paraffin-embedded, and sectioned at 8 mm thickness.
Slides were stained for Safranin-O/hematoxylin/fast green
using a standard protocol.40
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Statistical analysis
Statistical analysis was performed with the JMP Pro soft-
ware package. Luminescence data and biomaterial-mediated
delivery qRT-PCR data were analyzed using analysis of
variance (ANOVA) with Dunnett’s post hoc test using NT as
the control (a= 0.05). A two-way ANOVA with Tukey’s
HSD post hoc test was used to analyze all ELISA data, pellet
biochemistry, and pellet qRT-PCR data (a= 0.05).
Results
Responsiveness of the NF-jB synthetic promoter
to IL-1a or TNF
PDiPSCs receiving the NRE-Luc vector responded to
1 ng/mL IL-1a and 20 ng/mL TNF with a 10.17 – 0.54- and
8.40 – 0.32-fold increase in luminescence after 72-h cyto-
kine stimulation, respectively (Fig. 2A).
Self-regulating attenuation of inflammation by iPSCs
Attenuation of inflammatory signaling was tested in Ccl2-
Luc reporter cells that produce luciferase in response to
inflammatory stimuli. After transduction, cells transduced
with either the NRE-IL1Ra or EF1a-IL1Ra lentivirus and
NT control cells were treated with IL-1a at a range of doses
from physiologic (0.1 ng/mL) to supraphysiologic (1 ng/
mL)41 and compared with cells without cytokine. In all
doses of IL-1a, by 4 h there was significantly less lumi-
nescence output in both NRE-IL1Ra and EF1a-IL1Ra
groups compared with NT control. This trend was sustained
up to 24 h in all doses in the NRE-IL1Ra groups and up to
72 h in all doses except 0.05 ng/mL of IL-1a (Fig. 2B)
( p < 0.01). This decrease in luminescence shows that there
was attenuation of IL-1 signaling with the NRE-IL1Ra
group and that this system is responsive at a range of cy-
tokine concentrations.
To evaluate the ability of these vectors to produce ther-
apeutic levels of IL-1Ra, unedited PDiPSCs were lentivi-
rally transduced with the NRE-IL1Ra or EF1a-IL1Ra
vectors, and IL-1Ra protein production was measured. The
transduced cells and NT control cells were administered
with IL-1a and compared with cells without cytokine.
Culture media were collected at 0, 4, 12, 24, and 72 h to
measure the production of IL-1Ra in response to an in-
flammatory challenge. NRE-IL1Ra groups had an increase
in IL-1Ra production over time and exhibited higher IL-1Ra
production with increased doses of IL-1a. There was a
significant increase in IL-1Ra production in the NRE-IL1Ra
groups challenged with IL-1a compared with the NRE-
IL1Ra cells without cytokine at 24 and 72 h ( p < 0.0001)
with 140.64 – 8.78 and 163.41 – 16.04 ng/mL IL-1Ra pro-
duced with 0.5 and 1 ng/mL IL-1a stimulation at 72 h,
FIG. 2. Cell response to cytokine stimulation in monolayer to determine the responsiveness of NRE-IL1Ra vector. (A)
NRE-Luc cells were stimulated with 20 ng/mL TNF-a or 1 ng/mL IL-1a, and luminescence was measured after 72 h. Bars
represent mean RLU – SEM (n = 4). (B) Fold change of NF-kB activity measured by luminescence signal from Ccl2-Luc
cells. Bars represent the mean fold change in RLU – SEM (n = 6). Asterisks represent significance ( p < 0.05) compared with
NT control. (C) NT and NRE-IL1Ra cells were treated with IL-1a, and an ELISA was performed on samples to determine
IL-1Ra protein production. Values represent mean – SEM (n = 4). Groups not sharing same letter are statistically significant
( p < 0.05). ELISA, enzyme-linked immunosorbent assay; NT, non-transduced; RLU, relative luminescence unit; SEM,
standard error of the mean; TNF-a, tumor necrosis factor-a. Color images are available online.
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respectively. Additionally, there was an increase in IL-1Ra in
NRE-IL1Ra groups compared with the NT and EF1a-IL1Ra
groups (Fig. 2C and Supplementary Fig. S1) ( p < 0.0001).
These results taken together show that this iPSC-based NRE-
IL1Ra system responds to an inflammation challenge by
producing increased levels of the biologic drug.
Transduced NRE-IL1Ra iPSCs form tissue-engineered
cartilage that is protected from IL-1a
Following lentiviral delivery to iPSCs and 21 days of
chondrogenic differentiation, pellets were administered 0.5
or 1 ng/mL IL-1a for 72 h and were compared with pellets
that did not receive cytokine. GFP control pellets showed
rich Safranin-O staining for sGAG, one of the primary
components of cartilage ECM. Pellets treated with 0.5 ng/
mL or 1 ng/mL IL-1a for 72 h displayed reduced Safranin-O
staining (Fig. 3A). Pellets made from NRE-IL1Ra PDiPSCs
produced 72.90 – 2.42 and 92.24 – 2.31 ng/mL IL-1Ra in
response to 0.5 and 1 ng/mL IL-1a, respectively, which was
significantly higher than both GFP and EF1a-IL1Ra pellets
( p < 0.0001). EF1a-IL1Ra pellets produced significantly
higher levels of IL-1Ra compared with GFP control pellets
(Fig. 3B) ( p < 0.001). NRE-IL1Ra pellets showed protection
against IL-1a-mediated matrix degradation, as indicated by
robust Safranin-O staining and quantitative biochemical
analysis. NRE-IL1Ra pellets that received IL-1a had sig-
nificantly higher amounts of sGAG when normalized to the
concentration of DNA in each pellet (normalized to pellets
that did not receive IL-1a) compared with EF1a-IL1Ra and
FIG. 3. Assessment of engineered cartilage to determine if NRE-IL1Ra protects tissues from cytokine stimulation. (A)
Safranin-O/fast green/hematoxylin-stained tissue sections of engineered cartilage (scale bar = 200mm). (B) IL-1Ra production
collected from media samples after IL-1a stimulation (n = 4). Groups not sharing same letter are statistically significant
( p < 0.05). (C) Percent conserved sGAG/DNA in pellets after the addition of IL-1a (n = 4). Groups not sharing same letter are
statistically significant ( p < 0.05). (D) Relative gene expression compared with 0 h control measured by qRT-PCR (n = 4).
Hash represents significance ( p < 0.05). Primer sequences are available in Supplementary Table S1. qRT-PCR, quantitative,
reverse transcription polymerase chain reaction; sGAG, sulfated glycosaminoglycan. Color images are available online.
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GFP control pellets (Fig. 3C) ( p = 0.0322 and 0.0005, re-
spectively). Despite the increased levels of IL-1Ra produc-
tion, the EF1a-IL1Ra pellets showed little or no inhibition
of IL-1a-mediated sGAG loss, as indicated by the loss of
Safranin-O staining and sGAG/DNA content (Fig. 3C).
Gene expression analysis of the pellets showed a signif-
icantly decreased expression of inflammation-related genes,
Ccl2 and Il6, in pellets engineered with the NRE-IL1Ra
vector compared with GFP control ( p = 0.0164 and 0.0004,
respectively) and EF1a-IL1Ra ( p = 0.0054 and 0.0008, re-
spectively) pellets. Furthermore, NRE-IL1Ra pellets had
significantly higher levels of expression of cartilage matrix-
related genes, Col2a1 and Acan, compared with GFP control
( p = 0.0088 and 0.0090, respectively) and EF1a-IL1Ra
pellets (Fig. 3D) ( p = 0.0044 and 0.041, respectively).
Biomaterial-mediated lentiviral delivery shows
self-regulating production of IL-1Ra
and attenuation of inflammation
Ccl2-Luc reporter cells were seeded on a PCL film and
were transduced through biomaterial-mediated delivery of
either NRE-IL1Ra or EF1a-IL1Ra vectors. Cell were also
seeded on PCL without virus as a NT control. Cells were
then administered with IL-1a. For all doses of IL-1a, the
NRE-IL1Ra group had significantly less luminescence out-
put compared with NT controls by 24 h ( p < 0.001)
(Fig. 4A). At 72 h post stimulation, NRE-IL1Ra and EF1a-
IL1Ra cells had decreased luminescent output compared
with NT controls in all doses, showing attenuation of in-
flammation ( p < 0.0001).
Culture media were collected at 0, 4, 12, 24, and 72 h to
measure IL-1Ra production from cells transduced via
biomaterial-mediated transduction. The NRE-IL1Ra group
exhibited a time- and dose-dependent response to IL-1Ra
production. IL-1Ra protein production was significantly
increased at higher doses of IL-1a, with 139.31 – 19.6 and
165.91 – 15.83 ng/mL IL-1Ra being produced when stimu-
lated with 0.5 and 1 ng/mL IL-1a, respectively, at 72 h
( p < 0.001). Additionally, IL-1Ra production was increased
in the NRE-IL1Ra group compared with NT and EF1a-
IL1Ra groups (Fig. 4B and Supplementary Fig. S2)
( p < 0.0001). There was an increase in Il1rn gene expression
in all cells that received the NRE-IL1Ra vector at 24 h
(Fig. 4C), and in EF1a-IL1Ra cells at 0, 12, and 24 h
(Supplementary Fig. S3C). By 72 h, NT and NRE-IL1Ra
groups were not significantly different from each other, in-
dicating that a decreased inflammatory signaling led to an
autoregulated decrease in Il1rn gene expression due to IL-
1Ra-mediated inhibition of inflammation and subsequent
gene circuit activation.
FIG. 4. Evaluation of cells transduced via biomaterial-
mediated lentiviral delivery. (A) Fold change of NF-kB
activity measured by luminescence signal from Ccl2-Luc
cells. Bars represent the mean fold change in RLU – SEM of
cells treated with IL-1a compared with controls cultured
with no cytokine (n = 6). Asterisks represent significance
( p < 0.05) compared with NT control. (B) NT and NRE-
IL1Ra cells were treated with IL-1a, and an ELISA was
performed on samples to determine IL-1Ra protein pro-
duction. Values represent mean – SEM (n = 4). Groups not
sharing same letter are statistically significant ( p < 0.05).
(C) Il1rn gene expression. Fold changes were determined
relative to 0 h NT cells without cytokine. Error bars repre-
sent means of fold change – SEM (n = 6). Primer sequences
are available in Supplementary Table S1. Color images are
available online.
‰
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Gene expression analysis showed a dose-dependent in-
crease in inflammation-related genes, Ccl2 and Il6, as early
as 4 h following the delivery of inflammatory cytokines to
all groups of cells, which persisted through 72 h. However,
the biomaterial-mediated delivery of the self-regulating
NRE-IL1Ra compared with NT controls significantly de-
creased the expression of Ccl2 starting at 4 h and was
maintained through 72 h (Fig. 5A) ( p < 0.01). Ccl2 was also
decreased in EF1a-IL1Ra cells compared with NT controls
at 24 and 72 h (Supplementary Fig. S3A). Il6 was signifi-
cantly decreased in NRE-IL1Ra cells from 4 h through 24 h
(Fig. 5B) ( p < 0.0001) and was significantly decreased in
EF1a-IL1Ra cells at 24 h (Supplementary Fig. S3B). To-
gether, these results show that this system responds to in-
flammatory stimulus and suggests that the therapeutic levels
produced could inhibit inflammation. Additionally, these
findings show a successful proof-of-concept experiment for
the delivery of either our transduced cells for implantation
into the joint6,24,42 or of our gene therapy vectors for
transduction of endogenous cells in vivo.
Discussion
A significant challenge in the field of regenerative
medicine has been the ability to tissue-engineer cartilage
that is capable of withstanding the harsh inflammatory
environment of an injured or arthritic joint. We developed
an iPSC-based lentiviral system in which cells sense and
respond to inflammatory stimuli by producing anti-
inflammatory mediators. Using a combination of regener-
ative medicine, synthetic biology, and gene therapy, we
developed self-regulating iPSCs that are capable of form-
ing engineered cartilage for the replacement of diseased
tissue and mitigating the inflammatory effects of IL-1a.35
Additionally, the versatility of both the iPSCs and the
lentiviral system allows for translation to various cell types
or tissues. Lastly, by leveraging the flexibility of lentiviral
transduction in tissue engineering applications, we dem-
onstrated proof-of-concept of a targeted delivery method
allowing for spatial control of therapy via biomaterial-
mediated lentiviral transduction.
Using lentivirus-based gene therapy, we engineered
iPSCs with the NRE-IL1Ra vector, creating a system that
can dynamically respond to and attenuate NF-kB signaling.
Cells receiving the NRE-IL1Ra vector responded rapidly to
IL-1a as all groups had reduced inflammatory signaling by
4 h after stimulation. Importantly, NRE-IL1Ra cells re-
sponded to both physiologic and supraphysiologic doses of
IL-1a, and this response was sustained throughout 72 h for
all doses, except 0.05 ng/mL IL-1a. In addition, all doses of
IL-1a activated the synthetic promoter to produce thera-
peutic levels of IL-1Ra by 24 and 72 h and in a dose-
dependent manner. This dose response provides a controlled
production of the therapeutic drug in response to different
levels of inflammation. Cells that received the EF1a-IL1Ra
vector produced IL-1Ra, however, at a significantly lower
amount than the NRE-IL1Ra vector. This could be due to
the low production of the transgene from the constitutive
promoter, which has previously been reported in lentiviral
systems with constitutive reporters.43
FIG. 5. Gene expression of cells transduced through biomaterial-mediated delivery and challenged with IL-1a. Fold
changes were determined relative to 0 h NT cells without cytokine. Error bars represent means of fold change – SEM (n = 6).
Asterisks represent significance relative to NT control group ( p < 0.05). (A) Ccl2 gene expression. (B) Il6 gene expression.
Color images are available online.
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An important advance of this work is the application of
our lentiviral system in iPSCs. iPSCs are attractive for tissue
engineering and regenerative medicine because they can be
expanded, patient-matched, and differentiated into a variety
of different cell types to treat multiple tissues, overcoming
the limitations of other common cell sources.35,44 Here, we
show that the NRE-IL1Ra vector can be delivered to
PDiPSCs, and these cells can form cartilaginous tissues, and
that in the presence of 0.05 or 1 ng/mL IL-1a, engineered
cartilage pellets produced high levels of IL-1Ra. This indi-
cates the potential use of this system for the repair of dis-
eased articular cartilage and mitigation of inflammation
through a soluble release of IL-1Ra into the joint. We ob-
served less IL-1Ra production from tissue-engineered car-
tilage than cells in monolayer. This difference can be
attributed to the different differentiation states of the cells,
as well as their accessibility to the culture media. In pellets,
cells are embedded within a dense ECM, which may bind or
hinder the transport of IL-1Ra and/or IL-1a.45 Despite these
transport limitations, NRE-IL1Ra pellets were protected
from IL-1a-mediated degradation, as evidenced by rich
Safranin-O staining and significantly higher levels of sGAG/
DNA. Furthermore, NRE-IL1Ra pellets had decreased ex-
pression of inflammation-related genes, while cartilage
matrix-related genes were sustained, showing the attenua-
tion of inflammatory pathways and protection of the matrix.
In previous approaches, gene therapy for the treatment of
OA has been performed with plasmid DNA,46 retrovirus,47
lentivirus,48–50 and most commonly non-integrating viral
vectors such as adeno-associated virus.37,51–54 Lentiviral de-
livery is advantageous for this system due to its ability to
stably integrate into the genome of dividing and non-dividing
cells for long-term gene expression, its larger packaging ca-
pacity, low immunogenicity, and low cytotoxicity.55,56 The
vector used in this study is self-inactivating and, therefore,
replication-defective, overcoming safety concerns previously
associated with viral gene therapy.57–59 Additionally, our
group and others have shown that viral vectors can be im-
mobilized to biomaterial surfaces or scaffolds for the delivery
of therapeutic vectors to cells.6,24,25,42,60 Our study showed
that biomaterial-mediated delivery of NRE-IL1Ra from PCL
provided efficient transduction and effectively decreased in-
flammatory signaling. Specifically, biomaterial-mediated
transduction of NRE-IL1Ra significantly decreased the ex-
pression of inflammation-related genes, Ccl2 and Il6, and
stimulated high levels of IL-1Ra production in a dose-
dependent manner. These results indicate that this approach
provides an effective method for delivering therapeutic vec-
tors and can be applied for broader tissue engineering ap-
plications. This strategy could address limitations of existing
gene therapy approaches such as the loss of therapeutic
transgene expression over time when using non-integrating
delivery methods, lack of spatial control of transduction when
using systemic injections of vectors, and lack of controllable
or inducible production of transgenes when using constitutive
expression vectors.
Previously, investigators have developed various systems
for inflammation-inducible expression of pro-regenerative
or anti-inflammatory transgenes. Rachakonda et al. created
a self-limiting promoter construct that was based on trun-
cated promoter sequences of cyclooxygenase-2 upstream of
IL-4 to express IL-4 only in the presence of inflammation.61
Others have also created expression systems based on NF-
kB binding sequences for luciferase reporting vectors62,63
or inducible systems driving the expression of anti-
inflammatory mediators in adeno-associated viral vec-
tors.64,65 Previous work in our lab utilized CRISPR-Cas9
technology to genome-engineer stem cells capable of using
the endogenous systems within the cells to sense inflam-
mation and produce therapeutic transgenes.26 While this
system has specific advantages in terms of the precision of
CRISPR-based gene editing, by packaging our NRE-IL1Ra
system into a lentiviral expression cassette, we expand the
vector’s applicability to transduce different cell types and
tissues, such as mesenchymal stem cells, adipose-derived
stem cells, or primary cells such as articular chondrocytes or
synovial cells, all of which are commonly used in tissue
engineering or targeted for gene therapy but are more
challenging to edit with CRISPR-Cas9. The sensitivity of
the synthetic promoter can be tuned dependent on the se-
quence, number of tandem repeats, and neighboring regu-
latory elements, as well as through gene editing66 or
epigenetic modification67 of the cells’ receptors. Ad-
ditionally, other inflammatory cytokines, such as TNF, or
intracellular signaling components can be targeted for spe-
cific or broad inhibition of inflammation.
Our synthetic lentiviral system can create self-regulating
cells capable of sensing and responding to inflammation
with a therapeutic level of biologic drug. The continued de-
velopment of designer circuits through gene switches,68–70
microRNA classifiers,71,72 and synthetic transcription
systems73–75 provides a toolkit to engineer more complex
circuits with specialized control. This work adds to our
long-term goals of developing a molecular toolbox76,77 of
biological building blocks for novel synthetic applications in
mammalian cells for ameliorating chronic diseases.
The autoregulatory capabilities of this system allow ap-
plications for regenerative medicine or for use as a pre-
ventative approach to inflammatory disease. Applying this
methodology not only allows for protection against inflam-
mation to aid in cartilage repair, but also provides protection
of any tissue-engineered constructs inserted to help repair an
osteoarthritic joint or biomaterial-mediated lentiviral trans-
duction of any infiltrating cells through localized transduc-
tion. The customization aspect of this system and its
functionality in monolayer, an engineered tissue replace-
ment, and through scaffold-mediated delivery gives inno-
vative opportunities for effective treatments that are
applicable in a variety of diseases.
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